{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:25:39Z","timestamp":1791109539473,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T00:00:00Z","timestamp":1228953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2009,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The purpose of this study to compare the long\u2010term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early\u2010start group) or placebo for 6 months followed by rasagiline (delayed\u2010start group) in the TEMPO study. Subjects who chose to participate in an open\u2010label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (\u00b1SD) duration in the study was 3.6 \u00b1 2.1 years; 177 subjects received rasagiline for \u22655.0 years. Over the entire 6.5\u2010year follow\u2010up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1;\n                    <jats:italic>P<\/jats:italic>\n                    = 0.021) or 16% (SE 5.7;\n                    <jats:italic>P<\/jats:italic>\n                    = 0.006) in favor of the early\u2010start versus delayed\u2010start rasagiline group. Although the interaction between treatment and time was significant, values for the early\u2010start group were better than the delayed\u2010start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early\u2010start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). Compared to delayed start, early initiation of rasagiline provided long\u2010term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD. \u00a9 2008 Movement Disorder Society\n                  <\/jats:p>","DOI":"10.1002\/mds.22402","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T17:05:24Z","timestamp":1229015124000},"page":"564-573","source":"Crossref","is-referenced-by-count":108,"title":["Long\u2010term outcome of early versus delayed rasagiline treatment in early Parkinson's disease"],"prefix":"10.1002","volume":"24","author":[{"given":"Robert A.","family":"Hauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark F.","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Hurtig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Wojcieszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl J.","family":"Fitzer\u2010Attas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the TEMPO Open\u2010label Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,3,24]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1981.tb16772.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.12.1937"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.2.241"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(85)90168-2"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0047-6374(00)00144-5"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00929-7"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0481-5"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.20350"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2005.tb00043.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2005.41.6.893613"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.561"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100000068"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20789"},{"issue":"6","key":"e_1_2_7_17_2","first-page":"A105","article-title":"Treatment with rotigotine transdermal system may attenuate progression of disability in patients with early\u2010stage Parkinson's disease","volume":"64","author":"Watts RL","year":"2005","journal-title":"Neurology"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10191"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0892-0362(02)00221-0"},{"issue":"5","key":"e_1_2_7_20_2","first-page":"S10","article-title":"Slowing the progression of Alzheimer disease: methodologic issues","volume":"11","author":"Leber P","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21918"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22218"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.66.10_suppl_4.S58"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000201252.57661.e1"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22402","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.22402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:21:53Z","timestamp":1760966513000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.22402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,15]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,3,15]]}},"alternative-id":["10.1002\/mds.22402"],"URL":"https:\/\/doi.org\/10.1002\/mds.22402","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1140858.597946","asserted-by":"object"}]},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,15]]}}}